Skip to main content
OpenTrials
Completed

NCT Number: NCT02466165

Multiple Sclerosis: Associated Cardiometabolic Risks and Impact of Exercise Therapy

Multiple Sclerosis (MS) is the most common chronic inflammatory neurological disorder in young adults. Due to heterogeneous symptoms, MS patients are often more inactive than healthy controls, resulting in an inactivity related physiological profile. In healthy people, physical inactivity can contribute to the development of an increased cardiometabolic risk state including the combined presence of cardiovascular risk factors (increased cholesterol, elevated blood pressure, body fat, glucose intolerance/insulin resistance, inflammation and reduced heart function/autonomic control). In other populations, these secondary health complications can be, in part, reduced by physical exercise, which is often used as the primary treatment strategy. Since the impact of exercise on cardiovascular risk factors in MS is unknown the present project first aims to explore this in a pilot trial and a controlled research setting (during 12 weeks). A better understanding of the above described risk factors and underlying physiological mechanisms will reduce the incidence of preventable comorbidities in MS and will further improve the multidisciplinary treatment of MS patients and MS rehabilitation in particular. Interestingly, the investigators already reported an elevated prevalence of impaired glucose tolerance in MS, but it is not clear whether the cardiometabolic state in MS is also impaired. Therefore, in a second part, the researchers will explore whether MS patients present a higher risk to develop cardiovascular diseases, as measured by the assessment of various cardiovascular risk factors, compared to healthy controls.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multiple Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System Behavior Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Healthy Controls Immune System Diseases Motor Activity Nervous System Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

REVAL, Diepenbeek, Belgium

Loading trial locations.

About this study

In a first part, various cardiovascular risk factors will be determined in a group of MS patients (n=~16). These patients will be enrolled in a pilot trail, investigating the feasability and impact of a high intense interval exercise intervention (12 weeks high intensity interval training). After 12 weeks, baseline cardiovascular risk measurements will be repeated to determine the impact of high intensity interval training on these risk factors in MS.

In a second part, these cardiovascular risk factors in a larger group of MS patients (n=~50) will be compared to healthy controls (n=~25), in order to determine whether MS patients show an increased prevalence of cardiovascular risk factors, and thus an elevated risk to develop cardiovascular diseases.

In total, a group of 80 subjects (MS patients and HC) will be investigated throughout this study, with only MS patients participating in the pilot trial/exercise intervention.

Measurements of cardiovascular risk factors will include:

  • body composition (DEXA)
  • blood pressure and heart rate (Omron M4-I)
  • whole body glucose disposal (oral glucose tolerance test)
  • blood analysis: insulin, total cholesterol, high- density lipoprotein, low-density lipoprotein, plasma triglycerides, C-reactive protein and glycosylated haemoglobin.

Furthermore, a maximal exercise test (determination maximal heart rate, workload, lactate concentrations, etc) and an isometric/isokinetic strength test will be performed to determine the impact of the rehabilitation program in MS patients.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy controls:

  • male/female
  • 18 years
  • written informed consent (Declaration of Helsinki and ethical committee guidelines)

MS patients:

  • cfr healthy controls criteria, in addition:
  • Diagnosed MS according to the McDonald criteria
  • Expanded Disability Status Scale (EDSS) between 1 and 7
  • Being available for the complete study course

Exclusion criteria

  • other disorders
  • pregnancy
  • participation in another study
  • MS exacerbation 6 months prior to the start.
  • for the MS patients: contra-indication to perform physical exercise

Treatment and study plan

Physical exercise

Behavioral

Other names: combined (endurance and resistance) exercise programme

Primary outcomes

  1. dyslipidemia, as determined by the analysis of blood samples

    Time frame: change from baseline up to 12 weeks

    measured at baseline and after 12 of exercise Blood samples will be analysed to determine complete blood lipid profile.

  2. hypertension / blood pressure as determined by supine blood pressure measures

    Time frame: change from baseline up to 12 weeks

    measured at baseline and after 12 of exercise Blood pressure will be evaluated supine.

  3. body fat as determined by DEXA scan

    Time frame: change from baseline up to 12 weeks

    measured at baseline and after 12 weeks of exercise Body composition will be determined by means of a Dexa scan.

  4. glucose tolerance / insulin resistance as determined by oral glucose tolerance test

    Time frame: change from baseline up to 12 weeks

    measured at baseline and after 12 weeks of exercise Glucose tolerance will be evaluated by means of an oral glucose tolerance test. Collected blood samples will be analysed to determine insulin concentrations

  5. inflammation as determined by analysis of blood samples

    Time frame: change from baseline up to 12 weeks

    measured at baseline and after 12 weeks of exercise Blood samples, as collected during the oral glucose tolerance test, will be analysed to evaluate inflammation (CRP etc)

Secondary outcomes

  1. muscle strength of knee extensor/flexor and elbow extensor/flexor as determined by Biodex

    Time frame: change from baseline up to 12 weeks

    measured at baseline and after 12 weeks of exercise Muscle strength will be evaluated by means of the Biodex

  2. aerobic capacity as determined by a maximal endurance test on the bike

    Time frame: change from baseline up to 12 weeks

    measured at baseline and after 12 weeks of exercise Aerobic capacity will be tested during a maximal endurance test on the bike

  3. blood lactate concentrations during exercise as determined by a maximal endurance test on the bike

    Time frame: change from baseline up to 12 weeks

    measured at baseline and after 12 weeks of exercise Lactate concentrations (mmol/L) will be tested during a maximal endurance test on the bike

  4. heart function

    Time frame: change from baseline up to 12 weeks

    measured at baseline and after 12 and 24 weeks of exercise

Sponsors and collaborators

Lead sponsor

Bert Op't Eijnde

Other

Registry information

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Jun 9, 2015
Registry last updated
Jun 20, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.